Jonathan Sabio

Jonathan Sabio

Auto-generated profile, based on publicly available information

Jonathan Sabio

Owkin

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NMNaoual Menssouri
Naoual Menssouri
LPLoïc Poiraudeau
Loïc Poiraudeau
CHCarole HELISSEY
Carole HELISSEY
LBLudovic Bigot
Ludovic Bigot
JSJonathan Sabio
Jonathan Sabio
YLYohann Loriot
Yohann Loriot
Purpose: The androgen receptor axis inhibitors (ARPI; e.g., enzalutamide, abiraterone acetate) are administered in daily practice for men with metastatic castration-resistant prostate cancer (mCRPC). However, not all patients respond, and mechanisms of both primary and acquired resistance remain largely unknown. Experimental Design: In the prospective trial MATCH-R (NCT02517892), 59 patients with mCRPC underwent whole-exome sequencing (WES) and/or RNA sequencing (RNA-seq) of samples collected before starting ARPI. Also, 18 patients with mCRPC underwent biopsy at time of resistance. The objectives were to identify genomic alterations associated with resistance to ARPIs as well as to describe clonal evolution. Associations of genomic and transcriptomic alterations with primary resistance were determined using Wilcoxon and Fisher exact tests. Results: WES analysis indicated that no single-gene genomic alterations were strongly associated with primary resistance. RNA-seq analysis showed that androgen receptor (AR) gene alterations and expression levels were similar between responders and nonresponders. RNA-based pathway analysis found that patients with primary resistance had a higher Hedgehog pathway score, a lower AR pathway score and a lower NOTCH pathway score than patients with a response. Subclonal evolution and acquisition of new alterations in AR-related genes or neuroendocrine differentiation are associated with acquired resistance. ARPIs do not induce significant changes in the tumor transcriptome of most patients; however, programs associated with cell proliferation are enriched in resistant samples. Conclusions: Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary ARPIs’ resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation. See related commentary by Slovin, p. 4323

25 November 2025
Verified
Other
Open access
NMNaoual Menssouri
Naoual Menssouri
LPLoïc Poiraudeau
Loïc Poiraudeau
CHCarole HELISSEY
Carole HELISSEY
LBLudovic Bigot
Ludovic Bigot
JSJonathan Sabio
Jonathan Sabio
YLYohann Loriot
Yohann Loriot
Supplementary data 11 describes the GSEA analysis of paired biopsies


25 November 2025
Verified
Other
Open access
NMNaoual Menssouri
Naoual Menssouri
LPLoïc Poiraudeau
Loïc Poiraudeau
CHCarole HELISSEY
Carole HELISSEY
LBLudovic Bigot
Ludovic Bigot
JSJonathan Sabio
Jonathan Sabio
YLYohann Loriot
Yohann Loriot
Supplementary Data 2 reports the DNA alterations from WES.

25 November 2025
Verified
Other
Open access
NMNaoual Menssouri
Naoual Menssouri
LPLoïc Poiraudeau
Loïc Poiraudeau
CHCarole HELISSEY
Carole HELISSEY
LBLudovic Bigot
Ludovic Bigot
JSJonathan Sabio
Jonathan Sabio
YLYohann Loriot
Yohann Loriot
The supplementary Data 1 describes the clinical characteristics of patients included in the analysis.

25 November 2025
Verified
Other
Open access
NMNaoual Menssouri
Naoual Menssouri
LPLoïc Poiraudeau
Loïc Poiraudeau
CHCarole HELISSEY
Carole HELISSEY
LBLudovic Bigot
Ludovic Bigot
JSJonathan Sabio
Jonathan Sabio
YLYohann Loriot
Yohann Loriot
Supplementary Data 8 describes GSEA analysis with overexpressed and underexpressed gene sets in primary resistant samples.